Industry Trends and Predictions 2026: VIVEbiotech Featured in Drug Discovery World
Natalia Elizalde, PhD, Chief Business Development Officer at VIVEbiotech, shares insights on the evolution of gene therapy and the growing relevance of in vivo lentiviral vector platforms.
Drug Discovery World’s Winter 2025/2026 issue has just been published — and it includes a contribution from Natalia Elizalde, PhD, Chief Business Development Officer at VIVEbiotech.
In this edition, Elizalde highlights a major shift taking place in the gene therapy field:
- The accelerating move toward in vivo applications using lentiviral vectors.
- The growing confidence in the safety and efficiency of lentiviral platforms.
- Key industry drivers such as advances in vector engineering, manufacturing scalability, and regulatory clarity.
As a GMP-certified manufacturer supporting both ex vivo and in vivo applications, VIVEbiotech is currently working on 12 in vivo programs, reinforcing the strong momentum lentiviral‑based therapies are gaining heading into 2026.
👉 A must-read for anyone following the evolution of cell and gene therapy.
🔗 Read the full article here:
https://www.ddw-online.com/ddw-winter-2025-2026-40076-202601/